The Food and Drug Administration cleared Alnylam Pharmaceuticals treatment for a progressive heart condition Thursday, setting it up to compete with therapies from BridgeBio and Pfizer.
Alnylams dru… [+638 chars]
Alnylam drug wins FDA approval for progressive heart disease - STAT
The FDA cleared Alnylam’s therapy for the heart disease ATTR-CM, setting the company up to compete with drugs from BridgeBio and Pfizer.
By:Elaine Chen
Source:STAT
Published:
Related News
business
business
business
Japan Government Bond Yields, Stocks Fall After Yen’s Rebound - The Wall Street Journal
The Wall Street Journal•The Wall Street Journal
Samsung Stock Gains as Nvidia AI Chip Supply Nears - TipRanks
South Korean market leader Samsung Electronics ($SSNLF) is set to begin production of its next-generation high-bandwidth memory chips, known as HBM4, as early as next month, according to a Reuters
Tipranks.com•Shalu Saraf
Yen Extends Gains Amid Threat of Intervention: Markets Wrap - Bloomberg.com
The dollar fell against all of its major peers after a rate check Friday by the Federal Reserve Bank of New York spurred speculation the US may assist Japan in efforts to boost the yen. Gold rose above $5,000 for the first time and US stock futures dropped wi…
Bloomberg•Anand Krishnamoorthy, Ruth Carson